

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Low-dose hydroxycarbamide therapy may offer similar... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1407/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1407" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings" />
    
            <meta name="og:title" content="F1000Research Article: Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.">
            <meta name="og:description" content="Read the latest article version by Baba Psalm Duniya Inusa, Wale Atoyebi, Abdul Aziz Hassan, Tushar Idhate, Livingstone Dogara, Ifeoma  Ijei, Yewen Qin, Kofi Anie, Juliana Olufunke  Lawson, Lewis Hsu, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15876">
            <meta name="article-id" content="14589">
            <meta name="dc.title" content="Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings">
            <meta name="dc.description" content="The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies (BABY-HUG) 9 to 18 months old (20 mg/kg per day) and developing countries such as India (10 mg/kg per day); however, there has been no direct comparison of the efficacy, effectiveness, or cost-effectiveness of these different regimens. The purpose of this review was to investigate the current situation with various hydroxycarbamide regimens with particular relevance to low-middle-income countries. In regard to methodology, a literature review was undertaken by using multiple databases in PubMed and Google and the search terms included sickle cell disease, hydroxyurea, hydroxycarbamide, sickle cell anaemia, low-middle-income countries, Sub-Saharan Africa, and India. Although MTD regimens have been widely used in research, especially within North America, clinical trials elsewhere tend to use fixed-dose regimens. In a survey of haematologists across Europe and Africa, 60% (75% response rate) did not use the MTD regimen for hydroxycarbamide treatment of sickle cell disease. The recommendations are (1) for practical purposes to commence using fixed-dose hydroxycarbamide in line with BABY-HUG recommendations and then (2) to consider or propose a trial comparing MTD escalation with various fixed doses and to include as end points health-related quality of life, haemoglobin F levels, adherence, and cost-effectiveness.">
            <meta name="dc.subject" content="sickle cell disease, hydroxyurea, hydroxycarbamide, low-middle income countries, anaemia">
            <meta name="dc.creator" content="Inusa, Baba Psalm Duniya">
            <meta name="dc.creator" content="Atoyebi, Wale">
            <meta name="dc.creator" content="Hassan, Abdul Aziz">
            <meta name="dc.creator" content="Idhate, Tushar">
            <meta name="dc.creator" content="Dogara, Livingstone">
            <meta name="dc.creator" content="Ijei, Ifeoma ">
            <meta name="dc.creator" content="Qin, Yewen">
            <meta name="dc.creator" content="Anie, Kofi">
            <meta name="dc.creator" content="Lawson, Juliana Olufunke ">
            <meta name="dc.creator" content="Hsu, Lewis">
            <meta name="dc.date" content="2018/09/04">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14589.1">
            <meta name="dc.source" content="F1000Research 2018 7:1407">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="sickle cell disease">
            <meta name="prism.keyword" content="hydroxyurea">
            <meta name="prism.keyword" content="hydroxycarbamide">
            <meta name="prism.keyword" content="low-middle income countries">
            <meta name="prism.keyword" content="anaemia">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/09/04">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1407">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14589.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1407">
            <meta name="citation_title" content="Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings">
            <meta name="citation_abstract" content="The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies (BABY-HUG) 9 to 18 months old (20 mg/kg per day) and developing countries such as India (10 mg/kg per day); however, there has been no direct comparison of the efficacy, effectiveness, or cost-effectiveness of these different regimens. The purpose of this review was to investigate the current situation with various hydroxycarbamide regimens with particular relevance to low-middle-income countries. In regard to methodology, a literature review was undertaken by using multiple databases in PubMed and Google and the search terms included sickle cell disease, hydroxyurea, hydroxycarbamide, sickle cell anaemia, low-middle-income countries, Sub-Saharan Africa, and India. Although MTD regimens have been widely used in research, especially within North America, clinical trials elsewhere tend to use fixed-dose regimens. In a survey of haematologists across Europe and Africa, 60% (75% response rate) did not use the MTD regimen for hydroxycarbamide treatment of sickle cell disease. The recommendations are (1) for practical purposes to commence using fixed-dose hydroxycarbamide in line with BABY-HUG recommendations and then (2) to consider or propose a trial comparing MTD escalation with various fixed doses and to include as end points health-related quality of life, haemoglobin F levels, adherence, and cost-effectiveness.">
            <meta name="citation_description" content="The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies (BABY-HUG) 9 to 18 months old (20 mg/kg per day) and developing countries such as India (10 mg/kg per day); however, there has been no direct comparison of the efficacy, effectiveness, or cost-effectiveness of these different regimens. The purpose of this review was to investigate the current situation with various hydroxycarbamide regimens with particular relevance to low-middle-income countries. In regard to methodology, a literature review was undertaken by using multiple databases in PubMed and Google and the search terms included sickle cell disease, hydroxyurea, hydroxycarbamide, sickle cell anaemia, low-middle-income countries, Sub-Saharan Africa, and India. Although MTD regimens have been widely used in research, especially within North America, clinical trials elsewhere tend to use fixed-dose regimens. In a survey of haematologists across Europe and Africa, 60% (75% response rate) did not use the MTD regimen for hydroxycarbamide treatment of sickle cell disease. The recommendations are (1) for practical purposes to commence using fixed-dose hydroxycarbamide in line with BABY-HUG recommendations and then (2) to consider or propose a trial comparing MTD escalation with various fixed doses and to include as end points health-related quality of life, haemoglobin F levels, adherence, and cost-effectiveness.">
            <meta name="citation_keywords" content="sickle cell disease, hydroxyurea, hydroxycarbamide, low-middle income countries, anaemia">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Baba Psalm Duniya Inusa">
            <meta name="citation_author_institution" content="Paediatric Haematology, Evelina London Children&rsquo;s Hospital, Guy&rsquo;s and St Thomas NHS Foundation Trust, London, UK">
            <meta name="citation_author" content="Wale Atoyebi">
            <meta name="citation_author_institution" content="Department of Haematology, Oxford University Teaching Hospital, Oxford, UK">
            <meta name="citation_author" content="Abdul Aziz Hassan">
            <meta name="citation_author_institution" content="Department of Haematology &amp; Blood Transfusion, Faculty of Basic Clinical Sciences, College of Health Sciences, Ahmadu Bello University &amp; ABU Teaching Hospital, Zaria, Nigeria">
            <meta name="citation_author" content="Tushar Idhate">
            <meta name="citation_author_institution" content="Division of Paediatric Haematology and Oncology, Department of Paediatrics, Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, India">
            <meta name="citation_author" content="Livingstone Dogara">
            <meta name="citation_author_institution" content="Haematology and Blood Transfusion, Faculty of Clinical Sciences, Kaduna State University College of Medicine, Kaduna State University, Kaduna, Nigeria">
            <meta name="citation_author" content="Ifeoma  Ijei">
            <meta name="citation_author_institution" content="Haematology and Blood Transfusion, Faculty of Clinical Sciences, Kaduna State University College of Medicine, Kaduna State University, Kaduna, Nigeria">
            <meta name="citation_author" content="Yewen Qin">
            <meta name="citation_author_institution" content="Paediatrics Department, University Hospital, Lewisham and Greenwich NHS Trust, King's College London, London, UK">
            <meta name="citation_author" content="Kofi Anie">
            <meta name="citation_author_institution" content="Haematology and Sickle Cell Centre, London North West University Healthcare NHS Trust, London, UK">
            <meta name="citation_author_institution" content="Imperial College London, London, UK">
            <meta name="citation_author" content="Juliana Olufunke  Lawson">
            <meta name="citation_author_institution" content="Department of Paediatrics, Zankli Medical Centre, Abuja, Nigeria">
            <meta name="citation_author" content="Lewis Hsu">
            <meta name="citation_author_institution" content="Pediatric Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA">
            <meta name="citation_publication_date" content="2018/09/04">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1407">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14589.1">
            <meta name="citation_firstpage" content="1407">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1407/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1407.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15876 /> <input type=hidden id=articleId name=articleId value=14589 /> <input type=hidden id=xmlUrl value="/articles/7-1407/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1407-v1.xml"> <input type=hidden id=article_uuid value=5553fe4c-70eb-490e-bae7-2b11e39a7dc0 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14589.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14589.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1407"
  },
  "headline": "Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young...",
  "datePublished": "2018-09-04T16:34:49",
  "dateModified": "2018-09-04T16:34:49",
  "author": [
    {
      "@type": "Person",
      "name": "Baba Psalm Duniya Inusa"
    },    {
      "@type": "Person",
      "name": "Wale Atoyebi"
    },    {
      "@type": "Person",
      "name": "Abdul Aziz Hassan"
    },    {
      "@type": "Person",
      "name": "Tushar Idhate"
    },    {
      "@type": "Person",
      "name": "Livingstone Dogara"
    },    {
      "@type": "Person",
      "name": "Ifeoma  Ijei"
    },    {
      "@type": "Person",
      "name": "Yewen Qin"
    },    {
      "@type": "Person",
      "name": "Kofi Anie"
    },    {
      "@type": "Person",
      "name": "Juliana Olufunke  Lawson"
    },    {
      "@type": "Person",
      "name": "Lewis Hsu"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies (BABY-HUG) 9 to 18 months old (20 mg/kg per day) and developing countries such as India (10 mg/kg per day); however, there has been no direct comparison of the efficacy, effectiveness, or cost-effectiveness of these different regimens. The purpose of this review was to investigate the current situation with various hydroxycarbamide regimens with particular relevance to low-middle-income countries. In regard to methodology, a literature review was undertaken by using multiple databases in PubMed and Google and the search terms included sickle cell disease, hydroxyurea, hydroxycarbamide, sickle cell anaemia, low-middle-income countries, Sub-Saharan Africa, and India. Although MTD regimens have been widely used in research, especially within North America, clinical trials elsewhere tend to use fixed-dose regimens. In a survey of haematologists across Europe and Africa, 60% (75% response rate) did not use the MTD regimen for hydroxycarbamide treatment of sickle cell disease. The recommendations are (1) for practical purposes to commence using fixed-dose hydroxycarbamide in line with BABY-HUG recommendations and then (2) to consider or propose a trial comparing MTD escalation with various fixed doses and to include as end points health-related quality of life, haemoglobin F levels, adherence, and cost-effectiveness."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1407.html",
            "name": "Low-dose hydroxycarbamide therapy may offer similar benefit as maximum..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Low-dose hydroxycarbamide therapy may offer similar benefit as maximum... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15876 data-id=14589 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14589.1" data-recommended="" data-doi="10.12688/f1000research.14589.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1407/v1/pdf?article_uuid=5553fe4c-70eb-490e-bae7-2b11e39a7dc0" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14589-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14589-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14589-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Inusa BPD, Atoyebi W, Hassan AA <em>et al.</em> Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1407 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14589.1" target=_blank>https://doi.org/10.12688/f1000research.14589.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14589-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14589 id=track-article-signin-14589 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14589?target=/articles/7-1407.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15876 /> <input name=articleId type=hidden value=14589 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:baba.inusa@gstt.nhs.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Baba Psalm Duniya Inusa</span></a><a href="https://orcid.org/0000-0003-2643-765X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2643-765X</div><sup>1</sup>,&nbsp;</span><span class="">Wale Atoyebi<sup>2</sup>,&nbsp;</span><span class="">Abdul Aziz Hassan<sup>3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Tushar Idhate<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Livingstone Dogara<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Ifeoma Ijei<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Yewen Qin<sup>6</sup>,&nbsp;</span><span class="">Kofi Anie<sup>7,8</sup>,&nbsp;</span><span class="">Juliana Olufunke Lawson<sup>9</sup>,&nbsp;</span><span class="">Lewis Hsu<sup>10</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:baba.inusa@gstt.nhs.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Baba Psalm Duniya Inusa</span></a><a href="http://orcid.org/0000-0003-2643-765X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2643-765X</div><sup>1</sup>,&nbsp;</span><span class="">Wale Atoyebi<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Abdul Aziz Hassan<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Tushar Idhate<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Livingstone Dogara<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Ifeoma Ijei<sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Yewen Qin<sup>6</sup>,&nbsp;</span><span class=article-page-hidden-authors>Kofi Anie<sup>7,8</sup>,&nbsp;</span><span class="">Juliana Olufunke Lawson<sup>9</sup>,&nbsp;</span><span class="">Lewis Hsu<sup>10</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 04 Sep 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14589.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Paediatric Haematology, Evelina London Children&rsquo;s Hospital, Guy&rsquo;s and St Thomas NHS Foundation Trust, London, UK<br/> <sup>2</sup> Department of Haematology, Oxford University Teaching Hospital, Oxford, UK<br/> <sup>3</sup> Department of Haematology &amp; Blood Transfusion, Faculty of Basic Clinical Sciences, College of Health Sciences, Ahmadu Bello University &amp; ABU Teaching Hospital, Zaria, Nigeria<br/> <sup>4</sup> Division of Paediatric Haematology and Oncology, Department of Paediatrics, Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, India<br/> <sup>5</sup> Haematology and Blood Transfusion, Faculty of Clinical Sciences, Kaduna State University College of Medicine, Kaduna State University, Kaduna, Nigeria<br/> <sup>6</sup> Paediatrics Department, University Hospital, Lewisham and Greenwich NHS Trust, King's College London, London, UK<br/> <sup>7</sup> Haematology and Sickle Cell Centre, London North West University Healthcare NHS Trust, London, UK<br/> <sup>8</sup> Imperial College London, London, UK<br/> <sup>9</sup> Department of Paediatrics, Zankli Medical Centre, Abuja, Nigeria<br/> <sup>10</sup> Pediatric Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA<br/> <p> <div class=margin-bottom> Baba Psalm Duniya Inusa <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Validation, Visualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Wale Atoyebi <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Abdul Aziz Hassan <br/> <span>Roles: </span> Data Curation, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Tushar Idhate <br/> <span>Roles: </span> Methodology, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Livingstone Dogara <br/> <span>Roles: </span> Project Administration, Visualization, Writing  Review & Editing </div> <div class=margin-bottom> Yewen Qin <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Visualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Lewis Hsu <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=38286-37482></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=38284-37481></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have been used in babies (BABY-HUG) 9 to 18 months old (20 mg/kg per day) and developing countries such as India (10 mg/kg per day); however, there has been no direct comparison of the efficacy, effectiveness, or cost-effectiveness of these different regimens. The purpose of this review was to investigate the current situation with various hydroxycarbamide regimens with particular relevance to low-middle-income countries. In regard to methodology, a literature review was undertaken by using multiple databases in PubMed and Google and the search terms included sickle cell disease, hydroxyurea, hydroxycarbamide, sickle cell anaemia, low-middle-income countries, Sub-Saharan Africa, and India. Although MTD regimens have been widely used in research, especially within North America, clinical trials elsewhere tend to use fixed-dose regimens. In a survey of haematologists across Europe and Africa, 60% (75% response rate) did not use the MTD regimen for hydroxycarbamide treatment of sickle cell disease. The recommendations are (1) for practical purposes to commence using fixed-dose hydroxycarbamide in line with BABY-HUG recommendations and then (2) to consider or propose a trial comparing MTD escalation with various fixed doses and to include as end points health-related quality of life, haemoglobin F levels, adherence, and cost-effectiveness. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> sickle cell disease, hydroxyurea, hydroxycarbamide, low-middle income countries, anaemia </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Baba Psalm Duniya Inusa (<a href="mailto:baba.inusa@gstt.nhs.uk">baba.inusa@gstt.nhs.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Baba Psalm Duniya Inusa </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2018 Inusa BPD <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Inusa BPD, Atoyebi W, Hassan AA <em>et al.</em> Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1407 (<a href="https://doi.org/10.12688/f1000research.14589.1" target=_blank>https://doi.org/10.12688/f1000research.14589.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 04 Sep 2018, <b>7</b>(F1000 Faculty Rev):1407 (<a href="https://doi.org/10.12688/f1000research.14589.1" target=_blank>https://doi.org/10.12688/f1000research.14589.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 04 Sep 2018, <b>7</b>(F1000 Faculty Rev):1407 (<a href="https://doi.org/10.12688/f1000research.14589.1" target=_blank>https://doi.org/10.12688/f1000research.14589.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e332>Introduction</h2><p class="" id=d29303e335>Sickle cell disease (SCD) is an inherited autosomal recessive genetic disorder caused by the presence of haemoglobin S (HbS)<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. SCD is one of the most common genetic diseases in the world<sup><a href="#ref-3">3</a></sup>. It is estimated that there are over 300,000 annual births with SCD globally and that 80% are from Sub-Saharan Africa<sup><a href="#ref-4">4</a></sup>. In the UK, 1 in about 2,000 babies (300 babies annually) is born with SCD compared with over 100,000 annual births with SCD in Nigeria<sup><a href="#ref-5">5</a><a href="#ref-7">7</a></sup>. This condition is associated with lifelong risk of frequent hospitalisation, poor quality of life, and decreased life expectancy<sup><a href="#ref-1">1</a></sup>. Large gaps exist for SCD survival and care between high-income countries and low-middle-income countries (LMICs) (over 99% in East London will survive into adulthood, but less than 50% in Sub-Saharan Africa will reach their 10th birthday)<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Treatment for SCD, despite perhaps being the most prevalent inherited life-threatening disorder, has not received high priority in many countries<sup><a href="#ref-6">6</a>,<a href="#ref-10">10</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e382>Clinical complications of sickle cell disease</h2><p class="" id=d29303e385>The homozygous state (HbSS) is referred to as sickle cell anaemia (SCA) and accounts for over 70% of SCD in the UK<sup><a href="#ref-11">11</a></sup>. Other forms of SCD include co-inheritance of HbS with haemoglobin C (HbSC), which accounts for about 20% of SCD and generally is less severe than SCA. The central pathologic feature occurs in a deoxygenated state when haemoglobin undergoes paracrystal formation and affected red blood cells (RBCs) become distorted, developing into the characteristic sickle shape<sup><a href="#ref-2">2</a></sup>. These RBCs interact with other vascular entities, leading to further obstruction of small vessels, tissue ischaemia and infarction, and haemolysis. A complex cascade of vascular and endothelial reactions occurs, leading to further tissue damage<sup><a href="#ref-12">12</a></sup>. In early childhood, SCD presents with clinical complications, including acute pain, anaemia, and end organ damage (for example, 11% with overt stroke by 18 years<sup><a href="#ref-13">13</a></sup> and silent cerebral infarction in over 30% by age 15<sup><a href="#ref-14">14</a></sup>).</p><p class="" id=d29303e408>The hallmark of SCD is the occurrence of painful vaso-occlusion episodes, sometimes known as a pain crisis<sup><a href="#ref-15">15</a></sup>. This occurs when deformed erythrocytes (due to paracrystal formation) occlude the microvasculature, resulting in tissue infarction, oedema, and localised inflammation subsequent to downstream tissue anoxia<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. This can lead to necrosis of the end organs and tissues, and necrosis of the bone marrow is most frequent. Often multiple sites of bone are affected, so patients may present with dactylitis pain and/or swelling of the hands and feet<sup><a href="#ref-9">9</a></sup> or sudden generalised pain<sup><a href="#ref-18">18</a></sup>. Another complication is acute chest syndrome (ACS), which has a high mortality rate in children and adolescent patients with SCD<sup><a href="#ref-18">18</a></sup>. ACS is defined as (1) the presence of a new infiltrate on chest X-ray associated with (2) one or more symptoms of fever, cough, excess sputum, dyspnoea, or hypoxia<sup><a href="#ref-19">19</a></sup>. In order to reduce the severity of the disease, the most common preventive intervention before medications for SCD became available was regular blood transfusions<sup><a href="#ref-13">13</a></sup>.</p><div class=section><a name=d29303e443 class=n-a></a><h3 class=section-title>Hydroxycarbamide utilisation in sickle cell disease</h3><p class="" id=d29303e448>The drug known as hydroxycarbamide (HC) in the UK and hydroxyurea (HU) in the rest of the world is a ribonucleotide reductase inhibitor<sup><a href="#ref-20">20</a></sup>. The role of HC therapy in SCD was first conclusively proven in adults in the landmark Multicenter Study of HU in Patients with Sickle Cell Anaemia, a randomised double-blinded placebo-controlled trial using a maximum tolerated dose (MTD) regimen<sup><a href="#ref-21">21</a></sup>. The rate of sickle cell crises was 44% lower in the HC group than in the placebo group. Other complications that showed significant reduction were ACS cases and the need for blood transfusion. Additional data suggest an overall 40% reduction in mortality in the HC group, but the evidence is not rigorous<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d29303e463>In the phase I/II HUG-KIDS trial<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup> and then the BABY-HUG phase III clinical trial<sup><a href="#ref-21">21</a>,<a href="#ref-25">25</a></sup>, HC benefits in infants and children were reaffirmed to be similar to those observed in adult SCD. Additional safety factors of the drug were also investigated, and it was shown that HC did not seem to present any serious inhibition of child growth and development<sup><a href="#ref-23">23</a></sup>. The phase III BABY-HUG trial was a randomised double-blinded placebo-controlled trial with a larger sample population of 193 patients (9 to 18 months old) with either HbSS or HbS<sup>0</sup> thalassaemia but did not examine disease severity<sup><a href="#ref-25">25</a></sup>. Results of the BABY-HUG study supported earlier work; HC could be implemented even earlier in life, and there were no serious adverse effects<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. Acute events were significantly reduced by HC, but protection from organ damage to the spleen and kidney was not shown in the BABY-HUG study. The other important conclusion from BABY-HUG was that administering HC could be beneficial for patients who had not presented with severe manifestations of SCD in a prophylactic manner, rather than only for patients with multiple previous cases of pain crises or other complications. A brain protection indication for HC was shown in the landmark TWITCH (TCD With Transfusions Changing to Hydroxyurea) study, showing that HC therapy can be comparable to chronic blood transfusion in selected children at high risk for stroke<sup><a href="#ref-27">27</a></sup>.</p><p class="" id=d29303e503>Improving health for young people with SCD has the potential to promote an individuals well-being, reduce hospital admissions, and improve educational achievement<sup><a href="#ref-25">25</a>,<a href="#ref-28">28</a></sup>. A number of systematic reviews and US National Institutes of Health (NIH) guidelines recommend increased utilisation of HC in SCD<sup><a href="#ref-12">12</a>,<a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. HC was approved by the US Food and Drug Administration for adults in 1998 (<a target=xrefwindow href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm" id=d29303e522>https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm590096.htm</a>). NIH guidelines in the US recommend that providers offer hydroxyurea for children with SCA starting at 9 months of age<sup><a href="#ref-31">31</a></sup>. The British Society Of Haematology have recently published UK guidelines for the use of Hydroxycarbamide in adults and children, these have been summarised (<a href="#SF1">Supplementary File 1</a>)<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d29303e538>HC has multiple mechanisms of benefit for SCD. It increases foetal haemoglobin (HbF) expression, and the HbF blocks HbS polymerisation. HC reduces the quantities of platelets and white blood cells, further improving blood flow in patients with SCD<sup><a href="#ref-33">33</a></sup>. HC improves RBC hydration and flexibility and decreases abnormal adhesion between blood cells and the blood vessel wall. HC increases the formation of nitric oxide, which in turn stimulates guanylate cyclase activity<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>, which also enhances blood flow. HC is also reported to improve spleen and renal function<sup><a href="#ref-36">36</a></sup>. Together, these combine to produce the clinical and laboratory improvement observed in SCD.</p><p class="" id=d29303e557>The toxicities in HC therapy may be grouped according to short-term, medium-term, or long-term concerns<sup><a href="#ref-22">22</a></sup>. Short-term complications are predominantly haematological toxicities such as cytopenias. HC is an alkylating cytotoxic agent which is associated with dose-dependent marrow suppression. The main mechanism of action of HC is the suppression of mature erythrocytes and the increase in younger erythrocytes, which have a greater HbF production<sup><a href="#ref-36">36</a></sup>. Cytopenia due to HC is not selective to erythrocytes and may therefore lead to the risk of pancytopenia involving leucopoenia, increased risk of immunosuppression, thrombocytopenia, and reticulocytopenia.</p><p class="" id=d29303e568>Medium-term toxicity is reported with decreased sperm cells (azoospermia and oligospermia<sup><a href="#ref-23">23</a>,<a href="#ref-37">37</a></sup>), which might be transient. It should be noted that baseline sperm abnormalities are frequent in males with SCD, and rates are as high as 91%<sup><a href="#ref-37">37</a><a href="#ref-40">40</a></sup>. It could potentially alarm carers/parents and patients, hence the reluctance to accept the use of HC. An unproven lingering concern is the risk of secondary neoplasms<sup><a href="#ref-29">29</a></sup>, but recent studies on HC in myelodysplastic states show no increased risk of cancer<sup><a href="#ref-21">21</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e597>Hydroxycarbamide regimens in practice</h2><p class="" id=d29303e600>In addition, the authors conducted a survey of HC practice patterns in haematologists and paediatricians across the European Union and Sub-Saharan Africa in 2017. The response rate was 75%, representing 53 sites. The results (<a href="#T1">Table 1</a> and <a href="#T2">Table 2</a>) reveal that only 28% use the MTD as against 30% who base their treatment dosage on minimum effective dose whereas almost 45% are happy to randomly assign HC versus placebo in a clinical trial setting. Clinicians attitudes, though, might have changed since the time of that survey in 2017.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Starting hydroxycarbamide therapy in sickle cell disease.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d29303e620 class=n-a></a><thead><a name=d29303e622 class=n-a></a><tr><a name=d29303e624 class=n-a></a><th align=left colspan=3 rowspan=1><a name=d29303e626 class=n-a></a>What is the youngest age at which you would start<br class=br>treatment?</th></tr><tr><a name=d29303e632 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d29303e634 class=n-a></a>Answer</th><th align=left colspan=1 rowspan=1><a name=d29303e637 class=n-a></a>Count</th><th align=left colspan=1 rowspan=1><a name=d29303e640 class=n-a></a>Percentage</th></tr></thead><tbody><a name=d29303e645 class=n-a></a><tr><a name=d29303e647 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e648 class=n-a></a>06 months (A1)</td><td colspan=1 rowspan=1><a name=d29303e651 class=n-a></a>2</td><td colspan=1 rowspan=1><a name=d29303e654 class=n-a></a>3.85%</td></tr><tr><a name=d29303e657 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e658 class=n-a></a>6 months2 years (A2)</td><td colspan=1 rowspan=1><a name=d29303e661 class=n-a></a>22</td><td colspan=1 rowspan=1><a name=d29303e664 class=n-a></a>42.31%</td></tr><tr><a name=d29303e667 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e668 class=n-a></a>25 years (A3)</td><td colspan=1 rowspan=1><a name=d29303e671 class=n-a></a>10</td><td colspan=1 rowspan=1><a name=d29303e674 class=n-a></a>19.23%</td></tr><tr><a name=d29303e677 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e678 class=n-a></a>510 years (A4)</td><td colspan=1 rowspan=1><a name=d29303e681 class=n-a></a>1</td><td colspan=1 rowspan=1><a name=d29303e684 class=n-a></a>1.92%</td></tr><tr><a name=d29303e687 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e688 class=n-a></a>More than 10 years (A5)</td><td colspan=1 rowspan=1><a name=d29303e691 class=n-a></a>2</td><td colspan=1 rowspan=1><a name=d29303e694 class=n-a></a>3.85%</td></tr><tr><a name=d29303e698 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e699 class=n-a></a>Other</td><td colspan=1 rowspan=1><a name=d29303e702 class=n-a></a>5</td><td colspan=1 rowspan=1><a name=d29303e705 class=n-a></a>9.62%</td></tr><tr><a name=d29303e708 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e709 class=n-a></a>No answer</td><td colspan=1 rowspan=1><a name=d29303e712 class=n-a></a>1</td><td colspan=1 rowspan=1><a name=d29303e715 class=n-a></a>1.92%</td></tr><tr><a name=d29303e718 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e719 class=n-a></a>Not completed or not displayed</td><td colspan=1 rowspan=1><a name=d29303e722 class=n-a></a>9</td><td colspan=1 rowspan=1><a name=d29303e725 class=n-a></a>17.31%</td></tr></tbody></table></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Designing a clinical trial in sickle cell disease.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d29303e742 class=n-a></a><thead><a name=d29303e744 class=n-a></a><tr><a name=d29303e746 class=n-a></a><th align=left colspan=3 rowspan=1><a name=d29303e748 class=n-a></a>Would you be willing to randomly assign young<br class=br>children to hydroxycarbamide or placebo in a trial?</th></tr><tr><a name=d29303e754 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d29303e756 class=n-a></a>Answer</th><th align=left colspan=1 rowspan=1><a name=d29303e759 class=n-a></a>Count</th><th align=left colspan=1 rowspan=1><a name=d29303e762 class=n-a></a>Percentage</th></tr></thead><tbody><a name=d29303e767 class=n-a></a><tr><a name=d29303e769 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e770 class=n-a></a>No (A1)</td><td colspan=1 rowspan=1><a name=d29303e773 class=n-a></a>4</td><td colspan=1 rowspan=1><a name=d29303e776 class=n-a></a>7.69%</td></tr><tr><a name=d29303e779 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e780 class=n-a></a>Yes, children</td><td colspan=1 rowspan=1><a name=d29303e783 class=n-a></a>6</td><td colspan=1 rowspan=1><a name=d29303e786 class=n-a></a>11.54%</td></tr><tr><a name=d29303e789 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e790 class=n-a></a>Yes, children 6 months2 years</td><td colspan=1 rowspan=1><a name=d29303e793 class=n-a></a>23</td><td colspan=1 rowspan=1><a name=d29303e796 class=n-a></a>44.23%</td></tr><tr><a name=d29303e799 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e800 class=n-a></a>Yes, children 25 years (A4)</td><td colspan=1 rowspan=1><a name=d29303e803 class=n-a></a>23</td><td colspan=1 rowspan=1><a name=d29303e806 class=n-a></a>44.23%</td></tr><tr><a name=d29303e809 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e810 class=n-a></a>Yes, children 510 years</td><td colspan=1 rowspan=1><a name=d29303e813 class=n-a></a>21</td><td colspan=1 rowspan=1><a name=d29303e816 class=n-a></a>40.38%</td></tr><tr><a name=d29303e820 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e821 class=n-a></a>Yes, children older than 10 years</td><td colspan=1 rowspan=1><a name=d29303e824 class=n-a></a>21</td><td colspan=1 rowspan=1><a name=d29303e827 class=n-a></a>40.38%</td></tr><tr><a name=d29303e830 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e831 class=n-a></a>Other</td><td colspan=1 rowspan=1><a name=d29303e834 class=n-a></a>6</td><td colspan=1 rowspan=1><a name=d29303e837 class=n-a></a>11.54%</td></tr><tr><a name=d29303e840 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e841 class=n-a></a>Not completed or not displayed</td><td colspan=1 rowspan=1><a name=d29303e844 class=n-a></a>10</td><td colspan=1 rowspan=1><a name=d29303e847 class=n-a></a>19.23%</td></tr></tbody></table></div><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3></h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d29303e855 class=n-a></a><thead><a name=d29303e857 class=n-a></a><tr><a name=d29303e859 class=n-a></a><th align=left colspan=3 rowspan=1><a name=d29303e861 class=n-a></a>In a trial to study the effect of<br class=br>hydroxycarbamide in protecting against<br class=br>ischaemic cerebral damage, what dosage<br class=br>scheme would you prefer to use?</th></tr><tr><a name=d29303e871 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d29303e873 class=n-a></a>Answer</th><th align=left colspan=1 rowspan=1><a name=d29303e876 class=n-a></a>Count</th><th align=left colspan=1 rowspan=1><a name=d29303e879 class=n-a></a>Percentage</th></tr></thead><tbody><a name=d29303e884 class=n-a></a><tr><a name=d29303e886 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e887 class=n-a></a>Standard fixed dose (A1)</td><td colspan=1 rowspan=1><a name=d29303e890 class=n-a></a>11</td><td colspan=1 rowspan=1><a name=d29303e893 class=n-a></a>21.15%</td></tr><tr><a name=d29303e896 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e897 class=n-a></a>Escalation to maximum<br class=br>tolerated dose (A2)</td><td colspan=1 rowspan=1><a name=d29303e902 class=n-a></a>18</td><td colspan=1 rowspan=1><a name=d29303e905 class=n-a></a>34.62%</td></tr><tr><a name=d29303e908 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e909 class=n-a></a>No preference (A3)</td><td colspan=1 rowspan=1><a name=d29303e912 class=n-a></a>12</td><td colspan=1 rowspan=1><a name=d29303e915 class=n-a></a>23.08%</td></tr><tr><a name=d29303e918 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e919 class=n-a></a>No answer</td><td colspan=1 rowspan=1><a name=d29303e922 class=n-a></a>1</td><td colspan=1 rowspan=1><a name=d29303e925 class=n-a></a>1.92%</td></tr><tr><a name=d29303e928 class=n-a></a><td colspan=1 rowspan=1><a name=d29303e929 class=n-a></a>Not completed or not<br class=br>displayed</td><td colspan=1 rowspan=1><a name=d29303e934 class=n-a></a>10</td><td colspan=1 rowspan=1><a name=d29303e937 class=n-a></a>19.23%</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e946>Study goal</h2><p class="" id=d29303e949>The overarching question is whether low-dose HC will offer a benefit similar to that of MTD HC in children and young adults with SCD, especially in low-middle-income settings.</p><p class="" id=d29303e952>i) Is adherence to HC therapy significantly greater with a fixed low dose (FLD) than an MTD HC regimen?</p><p class="" id=d29303e955>ii) Is health-related quality of life (HRQOL) significantly greater with an FLD than an MTD HC regimen?</p><p class="" id=d29303e958>iii) Are the total health and social care costs of caring for this population significantly lower with an FLD than an MTD HC regimen and is the FLD regimen more cost effective?</p><p class="" id=d29303e962>iv) It is also possible that early onset initiation of HC treatment leads to more sustained retention of HbF and F cells<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d29303e969>In several studies, the choice of FLD HC seems to arise partially from theoretical concerns that HC therapy would cause significant immunosuppression and allow tropical diseases to overwhelm the patient with SCD, and so a lower dose was considered safer than MTD HC for initial clinical trials. In India, Uganda, and Nigeria, rates of malaria did not increase in the patients on HC at fixed dose<sup><a href="#ref-21">21</a>,<a href="#ref-42">42</a><a href="#ref-45">45</a></sup>. In the Nigerian study, 1 patient out of 28 had pulmonary tuberculosis reactivation after HC therapy, but it is not clear whether this is a greater risk than the background rate of tuberculosis<sup><a href="#ref-46">46</a></sup>. As of this writing, studies have not examined the risks of tropical infectious diseases with HC at MTD.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e989>Literature search methodology</h2><p class="" id=d29303e992>We used a combination of databases, including Medline (using PubMed query tools), Cochrane review, and Google search engines, to identify the following search terms: hydroxyurea/hydroxycarbamide, sickle cell disease, sickle cell anaemia, low-middle-income setting, Sub-Saharan Africa, and India.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e999>Results</h2><p class="" id=d29303e1002>Clinical trials have reported benefits for MTD HC and FLD HC, as summarised in a recent Cochrane review<sup><a href="#ref-15">15</a></sup>. The majority of existing clinical trials of HC have relied on the use of the MTD regimen where an incremental dosing system is adopted until a dose is achieved just below the onset of toxicity. The rationale for a MTD regimen is that pharmacokinetics and marrow tolerance for HC have high variation between individuals, leading to a personalised medicine approach<sup><a href="#ref-15">15</a></sup>. The advantage of the MTD strategy is providing the patient with the maximal clinical benefit of HC administration with a personalised dose, and this MTD HC has been integrated into the management regimen for treating SCD, particularly in high-income countries<sup><a href="#ref-36">36</a></sup>. The disadvantages of MTD are that patients may experience unwarranted side effects plus the burden of frequent blood tests and HC dose adjustments. This burden on the patients might account for low acceptance of HC. Other patients might not feel clinical benefit during the dose-escalation period and hence might give up on HC before attaining MTD.</p><p class="" id=d29303e1017>A regimen of FLD HC was exemplified by the BABY-HUG study, which randomly assigned children (9 to 18 months old) to a fixed dose of 20 mg/kg HC or placebo<sup><a href="#ref-19">19</a></sup>. The advantages of a low dose are that patients may experience less toxicity such as reduced risk of myelotoxicity and other dose-related toxicity and hence may not require frequent monitoring compared to that required for the MTD regimen. This implies that the FLD HC regimen will cost less than the MTD regimen for the patients and the health-care system (fewer lab tests and clinic visits). The disadvantage of low-dose HC is that some patients might not achieve the full clinical benefits of treatment.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e1027>Adherence</h2><p class="" id=d29303e1030>Taking HC consistently is necessary for effective treatment. Lack of adherence is widely recognised as a challenge<sup><a href="#ref-47">47</a></sup>. One factor that contributes to poor adherence is absence of immediate feeling of benefit when an HC dose is taken or subjective worsening if a dose is missed. In addition, HC only decreases severity of SCD but is not a complete cure, and so even a patient taking HC consistently can be disappointed to find that they still suffer complications of SCD. HC capsules have relatively easy storage requirements, but HC does need protection from excessive heat and direct sunlight (per HC package insert). Young children might need HC as a palatable liquid or as dissolving tablets, and access to these formulations might be more limited than to capsule formulations.</p><p class="" id=d29303e1037>Techniques have been developed to encourage good adherence to HC therapy, which could be applied to an LMIC context. Patients can be given encouragement verbally at frequent clinic visits. They can receive visual feedback that the HC effect is seen in their blood test results or long-term clinical course over several months<sup><a href="#ref-15">15</a></sup>. Medication bottle caps have been created with sensors to detect whether the bottle is opened daily. Cell phone apps have also been developed to provide encouragement (automated or human) and directly observed therapy by selfie photo<sup><a href="#ref-48">48</a></sup>. Additional personal monitoring techniques include assigning a peer mentor, patient navigator, or community health worker<sup><a href="#ref-49">49</a></sup>. No information could be found comparing adherence to MTD and FLD HC regimens.</p><p class="" id=d29303e1052>Health Related Quality of Life (HRQOL) as measured in multiple dimensions improves with HC treatment whether with a MTD or a fixed low dose<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. Moreover, HRQOL is generally accepted to incorporate different domains such as an individuals physical health, psychological state, social relationships, levels of independence, and relationship to important aspects of their environment. HRQOL focuses on how an individuals illness and treatment impacts different domains of their life and is not restricted to their physical functioning<sup><a href="#ref-52">52</a></sup>. For example, the PedsQL 4.0 is a multi-dimensional measure covering physical functioning, emotional functioning, social functioning, and school functioning, which includes three summary scores (total, physical health, and psychosocial health). The PedsQL can be used as a child self-report measure for children 5 to 18 years old and as a parent proxy measure for children 2 to 18 years old. Evidence suggests that the PedsQL is valid, reliable, and sensitive to changes in a childs condition over time<sup><a href="#ref-53">53</a></sup> and sensitive to cognitive development. In addition, the PedsQL has been found to differentiate between paediatric SCD populations and healthy populations<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. SCD can significantly harm HRQOL both acutely and chronically. HRQOL measures that were developed in the US or the UK might need to be validated for rigorous application in other countries and other languages.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e1080>Costs</h2><p class="" id=d29303e1083>Economic benefits have been reported with both regimens<sup><a href="#ref-25">25</a>,<a href="#ref-42">42</a>,<a href="#ref-56">56</a>,<a href="#ref-57">57</a></sup>. It is possible that an FLD with improved adherence in fact produces more economic benefits because the costs of surveillance are lower. Many of the studies conducted in Africa and India used the FLD strategy<sup><a href="#ref-51">51</a><a href="#ref-54">54</a></sup>. HC is not inherently expensive (for example, USD $1 for an adult on an FLD regimen in Nigeria)<sup><a href="#ref-46">46</a></sup>. However, the cost of daily HC might be a barrier for people with low incomes and no health insurance coverage.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e1113>Global implementation of hydroxycarbamide to treat sickle cell disease</h2><p class="" id=d29303e1116>HC could be expected to play a major role in global SCD treatment because, of all the currently available management regimens, this may be the most straightforward to successfully initiate in developing countries. The basis on which this claim is made is that it is the only therapy option that, in light of current research, has been shown to be actually capable of reducing the severity of SCD complications via a single intervention. Compared with other management options like blood transfusion, HC is the simplest to implement in a population; it is a once-daily oral therapy<sup><a href="#ref-24">24</a></sup>. This is a pragmatic plan that is particularly relevant to developing countries because of the often-low investment in resource availability.</p><p class="" id=d29303e1123>HC is probably more widely available across the world than other therapeutic options for SCD. The majority of developing countries do not have a robust blood-banking infrastructure for chronic blood transfusion and have limited access to haematopoietic stem cell transplant and pharmaceutical-grade L-glutamine<sup><a href="#ref-45">45</a></sup>.</p><p class="" id=d29303e1130>Stroke and other cerebrovascular damage are common in childhood SCD and are among the most devastating complications of SCD. The brain protection indication for HC<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup> would be important in many LMICs where chronic blood transfusions face greater problems with safety and availability than in the blood banks of high-income countries<sup><a href="#ref-58">58</a></sup>. Another HC indication that has received little attention has been priapism, but the potential to decrease suffering and impotence could be significant for quality of life<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d29303e1148>The more economically developed countries such as the US and the UK have designated SCD as a public health issue and so the quality of care is rising, which in these countries has meant that mortality rates in young patients have been lowered to less than 5%<sup><a href="#ref-31">31</a></sup>. Sub-Saharan Africa, which carries the highest burden of SCD morbidity and mortality, also lags in medical resources and expertise. Although new advances such as HC are welcomed (and understandably so), the inevitable question is whether the larger picture is being missed in Sub-Saharan Africa. In light of this discrepancy in the availability of medical knowledge and resources, there have been calls to increase and improve the sharing of research between developed and developing countries. It is hoped that, when such networking is stimulated, a more rounded understanding of the condition and its worldwide effects could be established, such as further investigation into the genetic diversity and environmental effects of SCD. Capacity-building around SCD can potentially stimulate broader and deeper biomedical resources in LMICs. In view of the issues and concerns that have been clearly documented in this paper in relation to HC access, costs and supportive care, we have proposed recommendations for the initiation, dosing and monitoring of HC in LMICs (<a href="#SF2">Supplementary File 2</a>). This will provide a template for further discussion and ultimately collaborative efforts involving clinical trials and international guidelines.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d29303e1161>Conclusions</h2><p class="" id=d29303e1164>The use of HC has shown favourable results in terms of improving patient outcomes and safety in adults and children, and so this intervention method provides a promising facet in the improvement of patient survival in SCD. However, one must remember the worldwide scale of the condition and how, in countries and locations where the disease is prevalent, management is often inadequate. Thus, the avenues of widening scientific collaboration between countries and their research may be an even more pressing issue, one that could form the framework for future developments in this ever-progressing field.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d29303e1 class=n-a></a><h2 class=main-title id=d29477>Author contributions</h2><p class=metadata-entry><a name=d29303e261 class=n-a></a><p id=d29303e263> First systematic review of the literature by Baba Inusa and Yewen Qin, updated systematic review by Abdul Aziz Hassan, Tushar Idhate, and Baba Inusa, detailed manuscript writing and editing by Lewis Hsu, Wale Atoyebi, and Baba Inusa, subsequent reviews and editing contribution from Livingstone Dogara, Ifeoma Ijei, Juliana Olufunke Lawson, and Kofi Anie.</p></p></div><div class=back-section><a name=d29303e1 class=n-a></a><h2 class=main-title id=d29479>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d29303e1171 class=n-a></a><h2 class=main-title id=d29303e1173>Acknowledgements</h2><p class="" id=d29303e1176>The authors wish to thank Miss Sharon Ndoro, Senior Paediatric Research Nurse for sickle cell disease, Evelina London Childrens Hospital, London for supporting Yewen Qin during his special study component placement while undertaking this review. We would like to thank Dr Paul Telfer, The Royal London and St Bart's NHS Trust for initial the Hydroxycabamide survey in Europe.</p></div><div class=back-section><a name=SM1 class=n-a></a><a name=SM1 class=n-a></a><h2 class=main-title id=d29303e1182>Supplementary material</h2><p class="" id=SF1> <b>Supplementary File 1. Summary of recommendations and an algorithm for the use of HC in adults and children with SCD from a British Society for Haematology guideline.</b> Based on review of current evidence, this guideline provides graded recommendations on indications for initiating HC as well as monitoring of effectiveness and toxicity. It aims to provide a platform for joint clinician and patient decision making as well as improve equity of access.</p><p class="" id=d29303e1191><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/14589/ae390555-de05-4439-9eef-f36818fdea6a_Supplementary_File_1.docx" id=d29303e1192>Click here to access the data</a>.</p><p class="" id=SF2> <b>Supplementary File 2. Recommendations for initiation, dosing and monitoring of HC in low middle income settings.</b> In recognition of the well documented limited access, cost and supportive care in low middle class countries, we provide suggested recommendations for initiating, the dosage and monitoring of HC mostly applicable to children. It incorporates the use of both the Lowest Effective Dose (LED) and Maximum Tolerated Dose (MTD) dependent on the indication for use.</p><p class="" id=d29303e1202><a target=xrefwindow href="https://f1000researchdata.s3.amazonaws.com/supplementary/14589/593e672a-7fa4-45ff-abf5-a19cfb56068d_Supplementary_File_2.docx" id=d29303e1203>Click here to access the data</a>.</p></div><div class=back-section><a name=d29303e1208 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d29675>References</h2><div class="section ref-list"><a name=d29303e1208 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716147814"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1215 class=n-a></a>Meier ER, Miller JL: Sickle cell disease in children. <i>Drugs.</i> 2012; <b>72</b>(7): 895906. <a target=xrefwindow id=d29303e1223 href="http://www.ncbi.nlm.nih.gov/pubmed/22519940">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1226 href="http://dx.doi.org/10.2165/11632890-000000000-00000">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1229 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3899685">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716147814">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d29303e1242 class=n-a></a>Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. <i>Lancet.</i> 2010; <b>376</b>(9757): 201831. <a target=xrefwindow id=d29303e1250 href="http://www.ncbi.nlm.nih.gov/pubmed/21131035">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1253 href="http://dx.doi.org/10.1016/S0140-6736(10)61029-X">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d29303e1262 class=n-a></a>Weatherall DJ: The inherited diseases of hemoglobin are an emerging global health burden. <i>Blood.</i> 2010; <b>115</b>(22): 43316. <a target=xrefwindow id=d29303e1270 href="http://www.ncbi.nlm.nih.gov/pubmed/20233970">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1273 href="http://dx.doi.org/10.1182/blood-2010-01-251348">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1276 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2881491">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d29303e1285 class=n-a></a>Meeting JW, Who: Management of haemoglobin disorders. Rep a Jt WHO-TIF Meet Nicosia, Cyprus [Internet]. 2007. <a target=xrefwindow id=d29303e1287 href="http://www.who.int/genomics/WHO-TIF_genetics_final.pdf">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d29303e1296 class=n-a></a>Dormandy E, James J, Inusa B, <i> et al.</i>: How many people have sickle cell disease in the UK? <i>J Public Health (Oxf).</i> 2017. <a target=xrefwindow id=d29303e1304 href="http://www.ncbi.nlm.nih.gov/pubmed/29294057">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1307 href="http://dx.doi.org/10.1093/pubmed/fdx172">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718883904"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1317 class=n-a></a>Chakravorty S, Williams TN: Sickle cell disease: a neglected chronic disease of increasing global health importance. <i>Arch Dis Child.</i> 2015; <b>100</b>(1): 4853. <a target=xrefwindow id=d29303e1325 href="http://www.ncbi.nlm.nih.gov/pubmed/25239949">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1328 href="http://dx.doi.org/10.1136/archdischild-2013-303773">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1331 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4285890">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718883904">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d29303e1344 class=n-a></a>Inusa BP, Daniel Y, Lawson JO, <i> et al.</i>: Sickle Cell Disease Screening in Northern Nigeria: The Co- Existence of - Thalassemia Inheritance. <i>Pediat Therapeut.</i> 2015; <b>5</b>: 262. <a target=xrefwindow id=d29303e1355 href="http://dx.doi.org/10.4172/2161-0665.1000262">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d29303e1364 class=n-a></a>Telfer P, Coen P, Chakravorty S, <i> et al.</i>: Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. <i>Haematologica.</i> 2007; <b>92</b>(7): 90512. <a target=xrefwindow id=d29303e1375 href="http://www.ncbi.nlm.nih.gov/pubmed/17606440">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1378 href="http://dx.doi.org/10.3324/haematol.10937">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732150329"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1387 class=n-a></a>Macharia AW, Mochamah G, Uyoga S, <i> et al.</i>: The clinical epidemiology of sickle cell anemia In Africa. <i>Am J Hematol.</i> 2018; <b>93</b>(3): 36370. <a target=xrefwindow id=d29303e1398 href="http://www.ncbi.nlm.nih.gov/pubmed/29168218">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1401 href="http://dx.doi.org/10.1002/ajh.24986">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732150329">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727641541"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1414 class=n-a></a>Piel FB, Steinberg MH, Rees DC: Sickle Cell Disease. <i>N Engl J Med.</i> 2017; <b>376</b>(16): 156173. <a target=xrefwindow id=d29303e1422 href="http://www.ncbi.nlm.nih.gov/pubmed/28423290">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1425 href="http://dx.doi.org/10.1056/NEJMra1510865">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727641541">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d29303e1438 class=n-a></a>Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service indicators. <i>Bull World Health Organ.</i> 2008; <b>86</b>(6): 4807. <a target=xrefwindow id=d29303e1446 href="http://www.ncbi.nlm.nih.gov/pubmed/18568278">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1449 href="http://dx.doi.org/10.2471/BLT.06.036673">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1452 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2647473">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d29303e1462 class=n-a></a>Hebbel RP, Osarogiagbon R, Kaul D: The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. <i>Microcirculation.</i> 2004; <b>11</b>(2): 12951. <a target=xrefwindow id=d29303e1470 href="http://www.ncbi.nlm.nih.gov/pubmed/15280088">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1473 href="http://dx.doi.org/10.1080/10739680490278402">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d29303e1482 class=n-a></a>Ohene-Frempong K, Weiner SJ, Sleeper LA, <i> et al.</i>: Cerebrovascular accidents in sickle cell disease: rates and risk factors. <i>Blood.</i> 1998; <b>91</b>(1): 28894. <a target=xrefwindow id=d29303e1493 href="http://www.ncbi.nlm.nih.gov/pubmed/9414296">PubMed Abstract </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d29303e1502 class=n-a></a>DeBaun MR, Gordon M, McKinstry RC, <i> et al.</i>: Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. <i>N Engl J Med.</i> 2014; <b>371</b>(8): 699710. <a target=xrefwindow id=d29303e1513 href="http://www.ncbi.nlm.nih.gov/pubmed/25140956">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1516 href="http://dx.doi.org/10.1056/NEJMoa1401731">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1520 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4195437">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d29303e1529 class=n-a></a>Matthews C, Walton EK, Inusa B: Sickle cell disease in childhood. <i>Student BMJ.</i> 2014; 22. <a target=xrefwindow id=d29303e1534 href="http://student.bmj.com/student/view-article.html?id=sbmj.g115">Reference Source</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d29303e1543 class=n-a></a>Sebastiani P, Nolan VG, Baldwin CT, <i> et al.</i>: A network model to predict the risk of death in sickle cell disease. <i>Blood.</i> 2007; <b>110</b>(7): 272735. <a target=xrefwindow id=d29303e1554 href="http://www.ncbi.nlm.nih.gov/pubmed/17600133">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1557 href="http://dx.doi.org/10.1182/blood-2007-04-084921">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1561 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1988954">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d29303e1570 class=n-a></a>Hebbel RP: Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. <i>Hematol Oncol Clin North Am.</i> 2014; <b>28</b>(2): 18198. <a target=xrefwindow id=d29303e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/24589261">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1581 href="http://dx.doi.org/10.1016/j.hoc.2013.11.005">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d29303e1591 class=n-a></a>Colombatti R, Sainati L: Management of Children With Sickle Cell Disease in Europe: Current Situation and Future Perspectives. 2016; 12935. <a target=xrefwindow id=d29303e1593 href="https://emj.europeanmedical-group.com/wp-content/uploads/sites/2/2016/07/Management-of-Children-With-Sickle-Cell-Disease-in-Europe-Current-Situation-and-Future-Perspectives.pdf">Reference Source</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d29303e1602 class=n-a></a>Strunk RC, Cohen RT, Cooper BP, <i> et al.</i>: Wheezing symptoms and parental asthma are associated with a physician diagnosis of asthma in children with sickle cell anemia. <i>J Pediatr.</i> 2014; <b>164</b>(4): 821826.e1. <a target=xrefwindow id=d29303e1613 href="http://www.ncbi.nlm.nih.gov/pubmed/24388323">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1616 href="http://dx.doi.org/10.1016/j.jpeds.2013.11.034">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1620 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3962704">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d29303e1629 class=n-a></a>Lebensburger JD, Howard T, Hu Y, <i> et al.</i>: Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. <i>Blood.</i> 2012; <b>119</b>(8): 191521. <a target=xrefwindow id=d29303e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/22130804">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1643 href="http://dx.doi.org/10.1182/blood-2011-08-374447">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3293645">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d29303e1656 class=n-a></a>Murad MH, Hazem A, Prokop L, <i> et al.</i>: Hydroxyurea for Sickle Cell Disease: A Systematic Review of Benefits, Harms, and Barriers of Utilization, 2012 Prepared for the National Heart, Lung, and Blood Institute (NHLBI) Prepared by the Knowledge and Encounter Research Unit., Mayo Clinic R. 2012; (165): 1116.</span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3621957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1668 class=n-a></a>Steinberg MH, McCarthy WF, Castro O, <i> et al.</i>: The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. <i>Am J Hematol.</i> 2010; <b>85</b>(6): 4038. <a target=xrefwindow id=d29303e1679 href="http://www.ncbi.nlm.nih.gov/pubmed/20513116">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1682 href="http://dx.doi.org/10.1002/ajh.21699">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2879711">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3621957">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d29303e1699 class=n-a></a>Kinney TR, Helms RW, O'Branski EE, <i> et al.</i>: Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. <i>Blood.</i> 1999; <b>94</b>(5): 15504. <a target=xrefwindow id=d29303e1710 href="http://www.ncbi.nlm.nih.gov/pubmed/10477679">PubMed Abstract </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d29303e1720 class=n-a></a>Thompson BW, Miller ST, Rogers ZR, <i> et al.</i>: The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. <i>Pediatr Blood Cancer.</i> 2010; <b>54</b>(2): 2505. <a target=xrefwindow id=d29303e1731 href="http://www.ncbi.nlm.nih.gov/pubmed/19731330">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1734 href="http://dx.doi.org/10.1002/pbc.22269">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1738 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2795081">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11575956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1747 class=n-a></a>Wang WC, Ware RE, Miller ST, <i> et al.</i>: Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). <i>Lancet.</i> 2011; <b>377</b>(9778): 166372. <a target=xrefwindow id=d29303e1758 href="http://www.ncbi.nlm.nih.gov/pubmed/21571150">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1761 href="http://dx.doi.org/10.1016/S0140-6736(11)60355-3">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3133619">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11575956">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726790588"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1778 class=n-a></a>Iughetti L, Bigi E, Venturelli D: Novel insights in the management of sickle cell disease in childhood. <i>World J Clin Pediatr.</i> 2016; <b>5</b>(1): 2534. <a target=xrefwindow id=d29303e1786 href="http://www.ncbi.nlm.nih.gov/pubmed/26862499">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1789 href="http://dx.doi.org/10.5409/wjcp.v5.i1.25">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4737690">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726790588">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726014408"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1805 class=n-a></a>Ware RE, Davis BR, Schultz WH, <i> et al.</i>: Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. <i>Lancet.</i> 2016; <b>387</b>(10019): 66170. <a target=xrefwindow id=d29303e1816 href="http://www.ncbi.nlm.nih.gov/pubmed/26670617">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1819 href="http://dx.doi.org/10.1016/S0140-6736(15)01041-7">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1823 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5724392">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726014408">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717954405"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1836 class=n-a></a>Thornburg CD, Files BA, Luo Z, <i> et al.</i>: Impact of hydroxyurea on clinical events in the BABY HUG trial. <i>Blood.</i> 2012; <b>120</b>(22): 430410; quiz 4448. <a target=xrefwindow id=d29303e1847 href="http://www.ncbi.nlm.nih.gov/pubmed/22915643">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1850 href="http://dx.doi.org/10.1182/blood-2012-03-419879">Publisher Full Text </a> | <a target=xrefwindow id=d29303e1854 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3507142">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717954405">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d29303e1867 class=n-a></a>Strouse JJ, Lanzkron S, Beach MC, <i> et al.</i>: Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. <i>Pediatrics.</i> 2008; <b>122</b>(6): 133242. <a target=xrefwindow id=d29303e1878 href="http://www.ncbi.nlm.nih.gov/pubmed/19047254">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1881 href="http://dx.doi.org/10.1542/peds.2008-0441">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718765104"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1891 class=n-a></a>Yawn BP, Buchanan GR, Afenyi-Annan AN, <i> et al.</i>: Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. <i>JAMA.</i> 2014; <b>312</b>(10): 103348. <a target=xrefwindow id=d29303e1902 href="http://www.ncbi.nlm.nih.gov/pubmed/25203083">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1905 href="http://dx.doi.org/10.1001/jama.2014.10517">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718765104">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d29303e1918 class=n-a></a>National Heart Lung and Blood Institute: Evidence-Based Management of Sickle Cell Disease: Expert Panel Report (EPR). <i>Guidel Expert Panel Rep.</i> 2014. <a target=xrefwindow id=d29303e1923 href="https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report 020816_0.pdf">Reference Source</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d29303e1931 class=n-a></a>Qureshi A, Kaya B, Pancham S, <i> et al.</i>: Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline. <i>Br J Haematol.</i> 2018; <b>181</b>(4): 460475. <a target=xrefwindow id=d29303e1942 href="http://www.ncbi.nlm.nih.gov/pubmed/29732531">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1945 href="http://dx.doi.org/10.1111/bjh.15235">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733801440"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e1954 class=n-a></a>Ware RE: Optimizing hydroxyurea therapy for sickle cell anemia. <i>Hematology Am Soc Hematol Educ Program.</i> 2015; <b>2015</b>(1): 43643. <a target=xrefwindow id=d29303e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/26637755">PubMed Abstract </a> | <a target=xrefwindow id=d29303e1965 href="http://dx.doi.org/10.1182/asheducation-2015.1.436">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733801440">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d29303e1978 class=n-a></a>Charache S: Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. <i>Semin Hematol.</i> 1997; <b>34</b>(3 Suppl 3): 1521. <a target=xrefwindow id=d29303e1986 href="http://www.ncbi.nlm.nih.gov/pubmed/9317197">PubMed Abstract </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d29303e1995 class=n-a></a>McGann PT, Ware RE: Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? <i>Curr Opin Hematol.</i> 2011; <b>18</b>(3): 15865. <a target=xrefwindow id=d29303e2003 href="http://www.ncbi.nlm.nih.gov/pubmed/21372708">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2006 href="http://dx.doi.org/10.1097/MOH.0b013e32834521dd">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2009 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3181131">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d29303e2019 class=n-a></a>Ware RE: How I use hydroxyurea to treat young patients with sickle cell anemia. <i>Blood.</i> 2010; <b>115</b>(26): 530011. <a target=xrefwindow id=d29303e2027 href="http://www.ncbi.nlm.nih.gov/pubmed/20223921">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2030 href="http://dx.doi.org/10.1182/blood-2009-04-146852">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2033 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2902131">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725264358"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e2042 class=n-a></a>DeBaun MR: Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review. <i>Expert Rev Hematol.</i> 2014; <b>7</b>(6): 76773. <a target=xrefwindow id=d29303e2050 href="http://www.ncbi.nlm.nih.gov/pubmed/25242414">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2053 href="http://dx.doi.org/10.1586/17474086.2014.959922">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725264358">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1160052"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e2066 class=n-a></a>Berthaut I, Guignedoux G, Kirsch-Noir F, <i> et al.</i>: Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. <i>Haematologica.</i> 2008; <b>93</b>(7): 98893. <a target=xrefwindow id=d29303e2077 href="http://www.ncbi.nlm.nih.gov/pubmed/18508803">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2080 href="http://dx.doi.org/10.3324/haematol.11515">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1160052">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d29303e2093 class=n-a></a>Nahoum CR, Fontes EA, Freire FR: Semen analysis in sickle cell disease. <i>Andrologia.</i> 1980; <b>12</b>(6): 5425. <a target=xrefwindow id=d29303e2101 href="http://www.ncbi.nlm.nih.gov/pubmed/7469046">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2104 href="http://dx.doi.org/10.1111/j.1439-0272.1980.tb01347.x">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d29303e2113 class=n-a></a>Fonagy P, Butler S, Goodyer I, <i> et al.</i>: Evaluation of multisystemic therapy pilot services in the Systemic Therapy for At Risk Teens (START) trial: study protocol for a randomised controlled trial. <i>Trials.</i> 2013; <b>14</b>: 265. <a target=xrefwindow id=d29303e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/23962220">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2127 href="http://dx.doi.org/10.1186/1745-6215-14-265">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2131 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3765214">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d29303e2140 class=n-a></a>Lebensburger JD, Miller ST, Howard TH, <i> et al.</i>: Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. <i>Pediatr Blood Cancer.</i> 2012; <b>59</b>(4): 6758. <a target=xrefwindow id=d29303e2151 href="http://www.ncbi.nlm.nih.gov/pubmed/22190441">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2154 href="http://dx.doi.org/10.1002/pbc.24037">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2158 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3337342">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d29303e2168 class=n-a></a>Patel DK, Mashon RS, Patel S, <i> et al.</i>: Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. <i>Hemoglobin.</i> 2012; <b>36</b>(5): 40920. <a target=xrefwindow id=d29303e2179 href="http://www.ncbi.nlm.nih.gov/pubmed/22881992">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2182 href="http://dx.doi.org/10.3109/03630269.2012.709897">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d29303e2191 class=n-a></a>Mtd T: Hypothesis I: A fixed low dose ( FLD ) of 20mg / Kg HU in children will be comparable to a maximum tolerated dose ( MTD ) in the elevation in HbF i ) Better drug adherence to FLD will lead to greater improvements in health-related quality of life compare. 36. </span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d29303e2200 class=n-a></a>Ansong D, Akoto AO, Ocloo D, <i> et al.</i>: Sickle cell disease: management options and challenges in developing countries. <i>Mediterr J Hematol Infect Dis.</i> 2013; <b>5</b>(1): e2013062. <a target=xrefwindow id=d29303e2211 href="http://www.ncbi.nlm.nih.gov/pubmed/24363877">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2214 href="http://dx.doi.org/10.4084/MJHID.2013.062">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2218 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3867228">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732015189"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d29303e2227 class=n-a></a>Opoka RO, Ndugwa CM, Latham TS, <i> et al.</i>: Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. <i>Blood.</i> 2017; <b>130</b>(24): 258593. <a target=xrefwindow id=d29303e2238 href="http://www.ncbi.nlm.nih.gov/pubmed/29051184">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2241 href="http://dx.doi.org/10.1182/blood-2017-06-788935">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732015189">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d29303e2254 class=n-a></a>Akingbola TS, Tayo B, Saraf SL, <i> et al.</i>: Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. <i>Blood.</i> 2017; <b>130</b>(Suppl 1): 981. <a target=xrefwindow id=d29303e2265 href="http://www.bloodjournal.org/content/130/Suppl_1/981">Reference Source</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d29303e2274 class=n-a></a>Musumadi L, Westerdale N, Appleby H: An overview of the effects of sickle cell disease in adolescents. <i>Nurs Stand.</i> 2012; <b>26</b>(26): 3540. <a target=xrefwindow id=d29303e2282 href="http://www.ncbi.nlm.nih.gov/pubmed/22482187">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2285 href="http://dx.doi.org/10.7748/ns2012.02.26.26.35.c8973">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d29303e2295 class=n-a></a>Badawy SM, Thompson AA, Lai JS, <i> et al.</i>: Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. <i>Health Qual Life Outcomes.</i> 2017; <b>15</b>(1): 136. <a target=xrefwindow id=d29303e2306 href="http://www.ncbi.nlm.nih.gov/pubmed/28679417">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2309 href="http://dx.doi.org/10.1186/s12955-017-0713-x">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5498866">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d29303e2322 class=n-a></a>Hsu LL, Green NS, Donnell Ivy E, <i> et al.</i>: Community Health Workers as Support for Sickle Cell Care. <i>Am J Prev Med.</i> 2016; <b>51</b>(1 Suppl 1): S8798. <a target=xrefwindow id=d29303e2333 href="http://www.ncbi.nlm.nih.gov/pubmed/27320471">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2336 href="http://dx.doi.org/10.1016/j.amepre.2016.01.016">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4918511">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d29303e2349 class=n-a></a>Eiser C, Morse R: Quality-of-life measures in chronic diseases of childhood. <i>Health Technol Assess.</i> 2001; <b>5</b>(4): 1157. <a target=xrefwindow id=d29303e2357 href="http://www.ncbi.nlm.nih.gov/pubmed/11262421">PubMed Abstract </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d29303e2366 class=n-a></a>Roncada C, Dias CP, Goecks S, <i> et al.</i>: Valor do emprego do questionrio WHOQOL-BREF na avaliao da qualidade de vida de pais de crianas com asma. <i>Rev Paul Pediatr.</i> 2015; <b>33</b>: 26874. <a target=xrefwindow id=d29303e2377 href="http://dx.doi.org/10.1016/j.rpped.2015.01.007">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d29303e2386 class=n-a></a>Aggarwal AN, Agarwal R, Gupta D: Abbreviated World Health Organization Quality of Life questionnaire (WHOQOL-Bref) in north Indian patients with bronchial asthma: an evaluation using Rasch analysis. <i>NPJ Prim Care Respir Med.</i> 2014; <b>24</b>: 14001. <a target=xrefwindow id=d29303e2394 href="http://www.ncbi.nlm.nih.gov/pubmed/24921608">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2397 href="http://dx.doi.org/10.1038/npjpcrm.2014.1">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2400 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4373256">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d29303e2409 class=n-a></a>Thornburg CD, Calatroni A, Panepinto JA: Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. <i>J Pediatr Hematol Oncol.</i> 2011; <b>33</b>(4): 2514. <a target=xrefwindow id=d29303e2417 href="http://www.ncbi.nlm.nih.gov/pubmed/21516020">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2420 href="http://dx.doi.org/10.1097/MPH.0b013e3182114c54">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2423 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3729442">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d29303e2433 class=n-a></a>Panepinto JA: Health-related quality of life in patients with hemoglobinopathies. <i>Hematology Am Soc Hematol Educ Program.</i> 2012; <b>2012</b>; 2849. <a target=xrefwindow id=d29303e2441 href="http://www.ncbi.nlm.nih.gov/pubmed/23233593">PubMed Abstract </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d29303e2450 class=n-a></a>Panepinto JA, Torres S, Bendo CB, <i> et al.</i>: PedsQL sickle cell disease module: feasibility, reliability, and validity. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(8): 133844. <a target=xrefwindow id=d29303e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/23441057">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2464 href="http://dx.doi.org/10.1002/pbc.24491">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2468 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4412167">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d29303e2477 class=n-a></a>Moore RD, Charache S, Terrin ML, <i> et al.</i>: Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. <i>Am J Hematol.</i> 2000; <b>64</b>(1): 2631. <a target=xrefwindow id=d29303e2488 href="http://www.ncbi.nlm.nih.gov/pubmed/10815784">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2491 href="http://dx.doi.org/10.1002/(SICI)1096-8652(200005)64:1%3C26::AID-AJH5%3E3.0.CO;2-F">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d29303e2500 class=n-a></a>Nottage KA, Hankins JS, Smeltzer M, <i> et al.</i>: Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. <i>PLoS One.</i> 2013; <b>8</b>(8): e72077. <a target=xrefwindow id=d29303e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/23967276">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2514 href="http://dx.doi.org/10.1371/journal.pone.0072077">Publisher Full Text </a> | <a target=xrefwindow id=d29303e2518 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3743768">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d29303e2527 class=n-a></a>Hankins JS, Helton KJ, McCarville MB, <i> et al.</i>: Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. <i>Pediatr Blood Cancer.</i> 2008; <b>50</b>(2): 2937. <a target=xrefwindow id=d29303e2538 href="http://www.ncbi.nlm.nih.gov/pubmed/17554794">PubMed Abstract </a> | <a target=xrefwindow id=d29303e2541 href="http://dx.doi.org/10.1002/pbc.21271">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Sep 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1407.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1407.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Paediatric Haematology, Evelina London Children&rsquo;s Hospital, Guy&rsquo;s and St Thomas NHS Foundation Trust, London, UK<br/> <sup>2</sup> Department of Haematology, Oxford University Teaching Hospital, Oxford, UK<br/> <sup>3</sup> Department of Haematology &amp; Blood Transfusion, Faculty of Basic Clinical Sciences, College of Health Sciences, Ahmadu Bello University &amp; ABU Teaching Hospital, Zaria, Nigeria<br/> <sup>4</sup> Division of Paediatric Haematology and Oncology, Department of Paediatrics, Mahatma Gandhi Mission Medical College and Hospital, Aurangabad, India<br/> <sup>5</sup> Haematology and Blood Transfusion, Faculty of Clinical Sciences, Kaduna State University College of Medicine, Kaduna State University, Kaduna, Nigeria<br/> <sup>6</sup> Paediatrics Department, University Hospital, Lewisham and Greenwich NHS Trust, King's College London, London, UK<br/> <sup>7</sup> Haematology and Sickle Cell Centre, London North West University Healthcare NHS Trust, London, UK<br/> <sup>8</sup> Imperial College London, London, UK<br/> <sup>9</sup> Department of Paediatrics, Zankli Medical Centre, Abuja, Nigeria<br/> <sup>10</sup> Pediatric Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA<br/> <p> <div class=margin-bottom> Baba Psalm Duniya Inusa <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Validation, Visualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Wale Atoyebi <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Abdul Aziz Hassan <br/> <span>Roles: </span> Data Curation, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Tushar Idhate <br/> <span>Roles: </span> Methodology, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Livingstone Dogara <br/> <span>Roles: </span> Project Administration, Visualization, Writing  Review & Editing </div> <div class=margin-bottom> Yewen Qin <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Visualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Lewis Hsu <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1407/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 04 Sep 2018, 7:1407 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14589.1">https://doi.org/10.12688/f1000research.14589.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2018 Inusa BPD <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15876 data-id=14589 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14589.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1407/v1/pdf?article_uuid=5553fe4c-70eb-490e-bae7-2b11e39a7dc0" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14589.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Inusa BPD, Atoyebi W, Hassan AA <em>et al.</em> Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1407 (<a href="https://doi.org/10.12688/f1000research.14589.1" target=_blank>https://doi.org/10.12688/f1000research.14589.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14589 id=mobile-track-article-signin-14589 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14589?target=/articles/7-1407.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15876 /> <input name=articleId type=hidden value=14589 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Laura Sainati</strong>, Pediatric Hematology-Oncology Unit, Department of Women's and Children's Health, Azienda Ospedaliera - University of Padova, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Winfred C. Wang</strong>, Department of Hematology, St Jude Children's Research Hospital, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 04 Sep 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1407.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1407.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=38286-37482></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=38284-37481></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1407/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>04 Sep 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Laura Sainati</strong>, Pediatric Hematology-Oncology Unit, Department of Women's and Children's Health, Azienda Ospedaliera - University of Padova, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Winfred C. Wang</strong>, Department of Hematology, St Jude Children's Research Hospital, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1407.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1407/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Low-dose hydroxycarbamide therapy may offer...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1407/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1407/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1407/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Inusa BPD et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1407/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1407",
            templates : {
                twitter : "Low-dose hydroxycarbamide therapy may offer similar benefit as.... Inusa BPD et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1407/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14589/15876")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15876");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "37481": 0,
                           "37482": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "6cbee771-4f69-42c9-964b-9a97b8a9324f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1407.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1407.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1407.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1407.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1407.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>